4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in the medical research technology and development of a non-invasive respiratory imaging solution using four-dimensional imaging. It offers CT:VQ, non contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of potential emphysema software; LTA provides visualization and quantification of the lung textures; PHA Analysis, a cutting-edge, fully-automated imaging solution; XV LVAS, a lung airflow imaging software; and XV Scanner, a lung function scanner. The company was incorporated in 2012 and is based in Carlton, Australia.
Metrics to compare | 4DX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4DXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −66.7x | −4.2x | −0.5x | |
PEG Ratio | 2.45 | 0.06 | 0.00 | |
Price/Book | 31.2x | 1.4x | 2.6x | |
Price / LTM Sales | 342.9x | 10.2x | 3.3x | |
Upside (Analyst Target) | −9.1% | 115.6% | 47.0% | |
Fair Value Upside | Unlock | −4.0% | 5.9% | Unlock |